North America Asthma and COPD Drug Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
North America Asthma and COPD Drug Market Analysis — Presence
Geographical Analysis
Click countries to exploreCountry Analysis
North America Asthma and COPD Drug Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| North America Asthma and COPD Drug Total | xxxx | xxxx | xxxx | 3.2% |
| United States | xxxx | xxxx | xxxx | xxxx |
| Canada | xxxx | xxxx | xxxx | xxxx |
| Mexico | xxxx | xxxx | xxxx | xxxx |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Drug Class breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Asthma and COPD Drug Market
The major players rapidly evolve with new strategies to attain a competitive edge and capture significant market share. The major asthma and COPD drug market participants emphasize expanding creative offerings to serve a large consumer base and gain a competitive benefit.
Asthma and COPD Drug Industry News
- In June 2022, Glenmark introduced a unique fixed dose combination (FDC) medication called Indacaterol + Mometasone for Indian patients with very severe asthma. The FDC was marketed under the trade name Indamet.
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| GlaxoSmithKline | ••• | ••• | ••• | ••• |
| AstraZeneca | ••• | ••• | ••• | ••• |
| Boehringer Ingelheim | ••• | ••• | ••• | ••• |
| Novartis | ••• | ••• | ••• | ••• |
| Merck & Co. | ••• | ••• | ••• | ••• |
| Sanofi | ••• | ••• | ••• | ••• |
| Pfizer | ••• | ••• | ••• | ••• |
| Teva Pharmaceutical Industries | ••• | ••• | ••• | ••• |
| F. Hoffmann‑La Roche | ••• | ••• | ••• | ••• |
| Others | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, the global Asthma and COPD Drug market size was estimated at USD 34512.2 Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 13804.88 million in 2023 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2023 to 2030. It is anticipated that the increase in money committed by both government and non-government entities will stimulate market expansion in this area. According to Cognitive Market Research, this kind of investment is probably going to raise awareness of asthma, which is going to boost medicine uptake for asthma therapy, which is going to spur vertical growth. The modern healthcare infrastructure and the local presence of major pharmaceutical companies are anticipated to drive market growth. In conclusion, the North American asthma and COPD drug market is thriving due to the rise in research and development efforts aimed at creating new treatments are all contributing to the market's growth.
- According to Cognitive Market Research, the US had a major share in the asthma and COPD drug market with a market size of USD 10892.05 million in 2023 and is projected to grow at a CAGR of 3.0% during the forecast period due to the growing hospital population and high population density.
- The Canada asthma and COPD drug market had a market share of USD 1656.59 million in 2023 and is projected to grow at a CAGR of 4.0% during the forecast period due to the existence of important manufacturing players, a tobacco-smoking habit, and a developed infrastructure.
- The Mexico asthma and COPD drug market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 1256.24 million in 2023.
The medical devices and consumables industry is growing rapidly, driven by aging populations, rising healthcare spending, and supportive regulations, boosting demand for implants, assistive tech, and home monitoring. Challenges include strict regulations, high R&D costs, and supply chain risks, but opportunities lie in emerging markets, health-tech partnerships, and eco-friendly devices. Key trends such as AI, precision medicine, and sustainable innovations are transforming healthcare and accelerating market growth.
Analyst Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The North America Asthma and COPD Drug Market Analysis is witnessing significant growth in the near future.
In 2023, the Bronchodilators segment accounted for a notable share of the North America Asthma and COPD Drug Market Analysis.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
Frequently Asked Questions
★ Reviews
Rate this report
North America Asthma and COPD Drug Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Drug Class | Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs |
|---|---|
| End User | Asthma Patients, COPD Patients |
| Distribution Channel | General Pharmacies, Hospital Pharmacies, Online Retailers |
| Therapy | Preventive, Curative |
| Route Of Administration | Oral, Inhaled, Intravenous, Subcutaneous |
| Age Group | Below 5, 5-14, 15-60, Above 60 |
| Prescription | Prescription, Over The Counter (OTC) |
| Drug Type | Branded, Generic |
| List of Competitors | GlaxoSmithKline Plc, Merck & Co Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Grifols S.A. |
Pricing, Access, and Affordability Analysis
-
Branded vs Generic Competition
-
Inhaler generics and substitution challenges
-
-
Biologic Drug Pricing and Patient Access
-
Cost-containment programs and payer negotiations
-
-
Patient Adherence and Cost Sensitivity
-
Out-of-pocket burden impact on therapy continuity
-
Patient Demographics & End-User Strategy
-
Pediatric Asthma Management Strategies
-
Safety, dosing flexibility, and adherence
-
-
Adult Population as Core Revenue Base
-
Long-term maintenance therapy demand
-
-
Geriatric COPD Management Challenges
-
Polypharmacy, comorbidities, and inhaler technique
-
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Top Players Ranking 2024
- 1.1.2 New Product Launch Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 GlaxoSmithKline Plc
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 R&D Investment (Subject to data availability)
- 1.2.1.4 Financials (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.2 Merck & Co Inc
- 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.2.2 Business Overview
- 1.2.2.3 R&D Investment (Subject to data availability)
- 1.2.2.4 Financials (Subject to data availability)
- 1.2.2.5 Product Types Specification
- 1.2.2.6 Business Strategy
- 1.2.2.7 Recent Developments
- 1.2.2.8 Management Change
- 1.2.2.9 S.W.O.T Analysis
- 1.2.3 AstraZeneca Plc
- 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.3.2 Business Overview
- 1.2.3.3 R&D Investment (Subject to data availability)
- 1.2.3.4 Financials (Subject to data availability)
- 1.2.3.5 Product Types Specification
- 1.2.3.6 Business Strategy
- 1.2.3.7 Recent Developments
- 1.2.3.8 Management Change
- 1.2.3.9 S.W.O.T Analysis
- 1.2.4 Boehringer Ingelheim GmbH
- 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.4.2 Business Overview
- 1.2.4.3 R&D Investment (Subject to data availability)
- 1.2.4.4 Financials (Subject to data availability)
- 1.2.4.5 Product Types Specification
- 1.2.4.6 Business Strategy
- 1.2.4.7 Recent Developments
- 1.2.4.8 Management Change
- 1.2.4.9 S.W.O.T Analysis
- 1.2.5 Novartis AG
- 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.5.2 Business Overview
- 1.2.5.3 R&D Investment (Subject to data availability)
- 1.2.5.4 Financials (Subject to data availability)
- 1.2.5.5 Product Types Specification
- 1.2.5.6 Business Strategy
- 1.2.5.7 Recent Developments
- 1.2.5.8 Management Change
- 1.2.5.9 S.W.O.T Analysis
- 1.2.6 Pfizer Inc.
- 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.6.2 Business Overview
- 1.2.6.3 R&D Investment (Subject to data availability)
- 1.2.6.4 Financials (Subject to data availability)
- 1.2.6.5 Product Types Specification
- 1.2.6.6 Business Strategy
- 1.2.6.7 Recent Developments
- 1.2.6.8 Management Change
- 1.2.6.9 S.W.O.T Analysis
- 1.2.7 Teva Pharmaceutical Industries Ltd
- 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.7.2 Business Overview
- 1.2.7.3 R&D Investment (Subject to data availability)
- 1.2.7.4 Financials (Subject to data availability)
- 1.2.7.5 Product Types Specification
- 1.2.7.6 Business Strategy
- 1.2.7.7 Recent Developments
- 1.2.7.8 Management Change
- 1.2.7.9 S.W.O.T Analysis
- 1.2.8 Grifols S.A.
- 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.8.2 Business Overview
- 1.2.8.3 R&D Investment (Subject to data availability)
- 1.2.8.4 Financials (Subject to data availability)
- 1.2.8.5 Product Types Specification
- 1.2.8.6 Business Strategy
- 1.2.8.7 Recent Developments
- 1.2.8.8 Management Change
- 1.2.8.9 S.W.O.T Analysis
- 1.2.1 GlaxoSmithKline Plc
- 1.1 Top Competitors Analysis
Chapter 2. Global Asthma and COPD Drug Market Analysis
- 2.1 Global Asthma and COPD Drug Market Analysis
- 2.2 Global Asthma and COPD Drug Market Analysis by Drug Class
- 2.3 Global Asthma and COPD Drug Market Analysis by End User
- 2.4 Global Asthma and COPD Drug Market Analysis by Distribution Channel
- 2.5 Global Asthma and COPD Drug Market Analysis by Therapy
- 2.6 Global Asthma and COPD Drug Market Analysis by Route Of Administration
- 2.7 Global Asthma and COPD Drug Market Analysis by Age Group
- 2.8 Global Asthma and COPD Drug Market Analysis by Prescription
- 2.9 Global Asthma and COPD Drug Market Analysis by Drug Type
Chapter 3. North America Asthma and COPD Drug Market Analysis
- 3.1 North America Asthma and COPD Drug Market Analysis
- 3.2 North America Asthma and COPD Drug Market Analysis by Country
- 3.3 North America Asthma and COPD Drug Market Analysis by Drug Class
- 3.4 North America Asthma and COPD Drug Market Analysis by End User
- 3.5 North America Asthma and COPD Drug Market Analysis by Distribution Channel
- 3.6 North America Asthma and COPD Drug Market Analysis by Therapy
- 3.7 North America Asthma and COPD Drug Market Analysis by Route Of Administration
- 3.8 North America Asthma and COPD Drug Market Analysis by Age Group
- 3.9 North America Asthma and COPD Drug Market Analysis by Prescription
- 3.10 North America Asthma and COPD Drug Market Analysis by Drug Type
- 3.11 North America Asthma and COPD Drug Market Analysis by Key Players
Chapter 4. United States Asthma and COPD Drug Market Analysis
- 4.1 United States Asthma and COPD Drug Market Analysis
- 4.2 United States Asthma and COPD Drug Market Analysis by Drug Class
- 4.3 United States Asthma and COPD Drug Market Analysis by End User
- 4.4 United States Asthma and COPD Drug Market Analysis by Distribution Channel
- 4.5 United States Asthma and COPD Drug Market Analysis by Therapy
- 4.6 United States Asthma and COPD Drug Market Analysis by Route Of Administration
- 4.7 United States Asthma and COPD Drug Market Analysis by Age Group
- 4.8 United States Asthma and COPD Drug Market Analysis by Prescription
- 4.9 United States Asthma and COPD Drug Market Analysis by Drug Type
- 4.10 United States Asthma and COPD Drug Market Analysis by Key Players
Chapter 5. Canada Asthma and COPD Drug Market Analysis
- 5.1 Canada Asthma and COPD Drug Market Analysis
- 5.2 Canada Asthma and COPD Drug Market Analysis by Drug Class
- 5.3 Canada Asthma and COPD Drug Market Analysis by End User
- 5.4 Canada Asthma and COPD Drug Market Analysis by Distribution Channel
- 5.5 Canada Asthma and COPD Drug Market Analysis by Therapy
- 5.6 Canada Asthma and COPD Drug Market Analysis by Route Of Administration
- 5.7 Canada Asthma and COPD Drug Market Analysis by Age Group
- 5.8 Canada Asthma and COPD Drug Market Analysis by Prescription
- 5.9 Canada Asthma and COPD Drug Market Analysis by Drug Type
- 5.10 Canada Asthma and COPD Drug Market Analysis by Key Players
Chapter 6. Mexico Asthma and COPD Drug Market Analysis
- 6.1 Mexico Asthma and COPD Drug Market Analysis
- 6.2 Mexico Asthma and COPD Drug Market Analysis by Drug Class
- 6.3 Mexico Asthma and COPD Drug Market Analysis by End User
- 6.4 Mexico Asthma and COPD Drug Market Analysis by Distribution Channel
- 6.5 Mexico Asthma and COPD Drug Market Analysis by Therapy
- 6.6 Mexico Asthma and COPD Drug Market Analysis by Route Of Administration
- 6.7 Mexico Asthma and COPD Drug Market Analysis by Age Group
- 6.8 Mexico Asthma and COPD Drug Market Analysis by Prescription
- 6.9 Mexico Asthma and COPD Drug Market Analysis by Drug Type
- 6.10 Mexico Asthma and COPD Drug Market Analysis by Key Players
Chapter 7. Drug Class Analysis
- 7.1 Bronchodilators
- 7.2 Monoclonal Antibodies
- 7.3 Anti-Inflammatory Drugs
- 7.4 Combination Drugs
Chapter 8. End User Analysis
- 8.1 Asthma Patients
- 8.2 COPD Patients
Chapter 9. Distribution Channel Analysis
- 9.1 General Pharmacies
- 9.2 Hospital Pharmacies
- 9.3 Online Retailers
Chapter 10. Therapy Analysis
- 10.1 Preventive
- 10.2 Curative
Chapter 11. Route Of Administration Analysis
- 11.1 Oral
- 11.2 Inhaled
- 11.3 Intravenous
- 11.4 Subcutaneous
Chapter 12. Age Group Analysis
- 12.1 Below 5
- 12.2 5-14
- 12.3 15-60
- 12.4 Above 60
Chapter 13. Prescription Analysis
- 13.1 Prescription
- 13.2 Over The Counter (OTC)
Chapter 14. Drug Type Analysis
- 14.1 Branded
- 14.2 Generic
Chapter 15. Qualitative Analysis (Subject to Data Availability)
- 15.1 Market Drivers
- 15.2 Market Restraints
- 15.3 Market Trends
- 15.4 Market Opportunity
- 15.5 Technological Road Map (Subject to Data Availability)
- 15.6 Product Life Cycle (Subject to Data Availability)
- 15.7 Customer and Buyer Behavior Analysis
- 15.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 15.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 15.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 15.7.4 Pricing, Affordability & Value Perception Analysis
- 15.7.5 Customer Segmentation & Demand Pattern Analysis
- 15.8 Industrial Chain Analysis (Subject to Data Availability)
- 15.8.1 Industry Chain Analysis
- 15.8.2 Manufacturing Cost Analysis
- 15.8.3 Supply Side Analysis
- 15.8.3.1 Raw Material Analysis
- 15.8.3.2 Raw Material Procurement Analysis
- 15.8.3.3 Raw Material Price Trend Analysis
- 15.9 PESTEL Analysis
- 15.9.1 Environmental Factors
- 15.9.2 Legal Factors
- 15.9.3 Technological Factors
- 15.9.4 Economic Factors
- 15.9.5 Political Factors
- 15.9.6 Social Factors
- 15.10 Porter’s Five Forces Analysis
- 15.10.1 Degree of Competition
- 15.10.2 Threat of Substitutes
- 15.10.3 Threat of New Entrants
- 15.10.4 Bargaining Power of Buyers
- 15.10.5 Bargaining Power of Suppliers
- 15.11 Patent Analysis (Subject to Data Availability)
- 15.12 ESG Analysis
- 15.13 Geopolitical Outlook
- 15.13.1 Global Power Realignment & Strategic Alliances
- 15.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 15.13.3 International Trade Relations & Market Access Environment
- 15.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 15.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 15.13.6 Technology Sovereignty & Digital Geopolitics
- 15.13.7 Strategic Implications for Investment, Growth & Market Entry
- 15.14 AI & Market Transformation
- 15.14.1 Competitive Landscape Disruption & Strategic Shifts
- 15.14.2 AI-Driven Transformation of Industry Value Chain
- 15.14.3 Evolution of Business Models & Revenue Streams
- 15.14.4 AI-Driven Product, Service & Innovation Transformation
- 15.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 16. Research Findings
- 16.1 Key Takeaways
- 16.2 Analyst Point of View
- 16.3 Assumptions and Acronyms
Chapter 17. Research Methodology and Sources
- 17.1 Primary Data Collection
- 17.1.1 Steps for Primary Data Collection
- 17.1.1.1 Identification of KOL
- 17.1.2 Backward Integration
- 17.1.3 Forward Integration
- 17.1.4 How Primary Research Help Us
- 17.1.5 Modes of Primary Research
- 17.1.1 Steps for Primary Data Collection
- 17.2 Secondary Research
- 17.2.1 How Secondary Research Help Us
- 17.2.2 Sources of Secondary Research
- 17.3 Data Validation
- 17.3.1 Data Triangulation
- 17.4 Data Representation
- 17.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the North America Asthma and COPD Drug Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Medical Devices and Consumables Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the North America Asthma and COPD Drug Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the north america asthma and copd drug market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
